Skip to main content

Advertisement

SpringerLink
Log in

Is it possible to modify the clinical course of Crohn's disease?

  • Viewpoint
  • Published:

From Nature Clinical Practice Gastroenterology & Hepatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Goekoop-Ruitermann YP et al. (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Inter Med 146: 406–415

    Article  Google Scholar 

  2. Rutgeerts P et al. (2006) Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated to Crohn's disease. Gastrointest Endosc 63: 433–442

    Article  Google Scholar 

  3. Frøslie KF et al. (2007) Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133: 412–422

    Article  Google Scholar 

  4. Ardizzone S et al. (2004) Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 127: 730–740

    Article  CAS  Google Scholar 

  5. Hanauer SB et al. (2004) Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127: 723–729

    Article  CAS  Google Scholar 

  6. Markowitz J et al. (2000) A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119: 895–902

    Article  CAS  Google Scholar 

  7. Hyams J et al. (2007) Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132: 863–873

    Article  CAS  Google Scholar 

  8. Colombel JF et al. (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132: 52–65

    Article  CAS  Google Scholar 

  9. Schreiber S et al. (2007) Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357: 239–250

    Article  CAS  Google Scholar 

  10. D'Haens G et al. (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371: 660–667

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. S Ardizzone is Head of the Inflammatory Bowel Disease Unit and G Bianchi Porro is Chair of Gastroenterology at L Sacco University Hospital, Milan, Italy.,

    Sandro Ardizzone & Gabriele Bianchi Porro

Authors
  1. Sandro Ardizzone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriele Bianchi Porro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sandro Ardizzone.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ardizzone, S., Porro, G. Is it possible to modify the clinical course of Crohn's disease?. Nat Rev Gastroenterol Hepatol 5, 428–429 (2008). https://doi.org/10.1038/ncpgasthep1178

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep1178

  • Springer Nature Limited

Search

Navigation